Back to top
more

Ligand Pharmaceuticals (LGND)

(Delayed Data from NSDQ)

$79.81 USD

79.81
69,602

-0.73 (-0.91%)

Updated Jun 20, 2024 04:00 PM ET

After-Market: $79.77 -0.04 (-0.05%) 6:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 249)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up

Merrimack (MACK) reported narrower-than-expected loss in the third quarter. With no marketed product after Onivyde sale, the company is now focused on developing its pipeline candidates.

    Pacira (PCRX) Posts Earnings in Q3, Revenues Lag Estimates

    Pacira's (PCRX) earnings surpassed estimates but sales missed the same in the third quarter of 2017. The company remains focused on the label expansion of Exparel.

      Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q3

      Catalyst Pharma (CPRX) remains focused on the development of its pipeline candidate firdapse in the third quarter of 2017.

        Mallinckrodt (MNK) Earnings, Sales Decline Y/Y in Q3

        Mallinckrodt (MNK) sales and earnings declined in the third-quarter due to volume Acthar declines.

          Agenus (AGEN) Reports In Line Loss in Q3, Revenues Lag

          Agenus (AGEN) incurred in line loss but sales missed estimates in the third quarter of 2017.

            Keryx (KERX) Q3 Loss Wider Than Expected, Stock Declines

            Keryx (KERX) posted wider-than-expected loss in the third quarter of 2017. The company also received approval for label expansion of its lead drug Auryxia.

              Alnylam's (ALNY) Q3 Earnings, Revenues Miss Estimates

              Alnylam Pharmaceuticals (ALNY) incurred wider than expected loss and missed sales estimates in the third quarter of 2017.

                Arena Pharmaceuticals (ARNA) Q3 Loss Widens Y/Y, Sales Beat

                Arena Pharmaceuticals (ARNA) reports another quarter of lackluster Belviq sales. However, the company is likely to advance ralinepag in phase III study based on positive data from the previous stage.

                  Prothena (PRTA) Earnings Beat in Q3, Pipeline in Focus

                  Prothena (PRTA) reported a narrower-than-expected loss in the third quarter as the company continued with its pipeline progress.

                    Key Predictions for Q3 Earnings Reports of PBYI, XON, LGND

                    The pharma/biotech industry has witnessed strong Q3 results with many companies beating estimates for earnings and sales. Let's see if some small biotechs, due to report on Nov 9, follow suit.

                      Endocyte (ECYT) Posts Narrower-than-Expected Q3 Loss

                      Endocyte (ECYT) posted narrower-than-expected loss in the third quarter of 2017. The company will focus on the development of PSMA-617 that it licensed in the same quarter.

                        What's in Store for Ligand (LGND) This Earnings Season?

                        Ligand's (LGND) Captisol formulation technology that helps it form partnerships with several leading healthcare companies might drive the stock in Q3.

                          ImmunoGen (IMGN) Q3 Loss Wider Than Expected, Cash View Up

                          ImmunoGen (IMGN) reports wider-than-expected loss in Q3. Revenues also lag expectations considerably.

                            Corcept (CORT) Q3 Earnings Miss Estimates, Guidance Raised

                            Corcept Therapeutics' (CORT) earnings miss but sales beat expectations in the third quarter of 2017. The company remains focused on advancing its cortisol modulation platform.

                              PDL BioPharma (PDLI) Q3 Earnings Beat, Revenues Rise Y/Y

                              PDL BioPharma's (PDLI) earnings top estimates in Q3. Revenues also grow year over owing to rise in royalty rights.

                                AMAG Pharma's (AMAG) Q3 Earnings Beat, Lowers '17 Outlook

                                AMAG Pharmaceuticals' (AMAG) earnings surpassed estimates but missed revenues in the third quarter of 2017.

                                  Alnylam Pharmaceuticals (ALNY) Soars: Stock Adds 10.3% in Session

                                  Alnylam Pharmaceuticals (ALNY) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

                                    Agios (AGIO) Q3 Loss Narrower than Expected, Revenues Up Y/Y

                                    Agios (AGIO) reports narrower-than-expected loss with revenues marginally beating estimates. The top line also improves year over year, thanks to reimbursement received from Celgene.

                                      Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q3

                                      Immune Design (IMDZ) reported narrower-than-expected loss and missed sales estimates in the third-quarter 2017.

                                        Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q3

                                        Epizyme (EPZM) posted narrower-than-expected loss in the third quarter of 2017. It plans to meet the FDA to begin the registration strategy for its lead pipeline candidate, tazemetostat, in the next quarter.

                                          Conatus (CNAT) Loss Wider Than Expected in Q3, Sales Miss

                                          Conatus (CNAT) reports wider-than-expected loss in Q3. However, revenues significantly increased year over year.

                                            Novo Nordisk (NVO) Tops Q3 Earnings Estimates, Lags Sales

                                            Novo Nordisk A/S (NVO) reported third-quarter 2017 earnings of 63 cents per American Depositary Receipt (ADR) beating the Zacks Consensus Estimate of 58 cents. In fact, the reported figure was ahead of 57 cents earned a year ago.

                                              Acorda (ACOR) Q3 Earnings Lag Estimates, Revenues Up Y/Y

                                              Acorda's (ACOR) performance in Q3 misses earnings and revenue estimates. However, the company's key drug Ampyra witnessed increase in sales year over year and inched up sequentially.

                                                Dr. Reddy's (RDY) Q2 Earnings and Revenues Decline Y/Y

                                                Dr. Reddy's (RDY) earnings declined year over year but revenues increased on a year-over-year basis. The company remains focused on launching new products.

                                                  Novartis Buys French Radiopharmaceutical Company

                                                  Novartis (NVS) plans to acquire France-based Advanced Accelerator Applications. The takeover will add RadioLigand Therapy, Lutathera, in its portfolio with potential to drive growth in the near term.